Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products for women. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. We have developed a proprietary transdermal patch technology called Skinfusion® designed to provide advantages over currently-available patches and is intended to optimize patch adherence and patient acceptability.

Our lead product candidate, Twirla™, also known as AG200-15, is a once-weekly contraceptive patch currently in Phase 3 clinical development. The United States, or U.S., prescription contraceptive market represents the greatest opportunity for Twirla with total market sales of $5.6 billion in 2013.

Agile Therapeutics is headquartered in Princeton, NJ.